Leslie Abromowitz
Child & Adolescent Psychiatry · Athens, OHNPI 1215969621
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 106 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 25.5% of the total. Reporting peaked in 2022 at $550 and has fallen 57.7% since, to $233 in 2025.
Across 106 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$527
- Otsuka America Pharmaceutical, Inc.$187
- Ironshore Pharmaceuticals Inc.$148
- Neurocrine Biosciences, Inc.$143
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$133
- Supernus Pharmaceuticals, Inc.$125
- plus $803 from 13 others
What the payments were for
- Food & beverage$1,98996%
- Education$774%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 31 | $527 |
| Otsuka America Pharmaceutical, Inc. | 8 | $187 |
| Ironshore Pharmaceuticals Inc. | 7 | $148 |
| Neurocrine Biosciences, Inc. | 9 | $143 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $133 |
| Supernus Pharmaceuticals, Inc. | 7 | $125 |
| Corium, LLC | 6 | $124 |
| Alkermes, Inc. | 3 | $121 |
| Johnson & Johnson | 5 | $98 |
| Vanda Pharmaceuticals Inc. | 4 | $95 |
| E.r. Squibb & Sons, L.L.C. | 5 | $91 |
| Axsome Therapeutics, Inc. | 4 | $79 |
| Sunovion Pharmaceuticals Inc. | 3 | $65 |
| Indivior Inc. | 2 | $45 |
| Tris Pharma Inc | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Neos Therapeutics, LP | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
How this compares
$2,066 in reported general payments places this provider in the 85th percentile of 160 child & adolescent psychiatry providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 39 | $15,076 |
| Aripiprazole | 72 | $3,814 |
| Lisdexamfetamine Dimesylate | 12 | $2,543 |
| Fluvoxamine Maleate | 23 | $1,008 |
| Quetiapine Fumarate | 25 | $756 |
| Duloxetine Hcl | 74 | $718 |
| Clozapine | 13 | $639 |
| Fluoxetine Hcl | 65 | $480 |
| Clonazepam | 44 | $342 |
| Trazodone Hcl | 72 | $307 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $288 |
| Sertraline Hcl | 47 | $241 |
| Lamotrigine | 36 | $228 |
| Hydroxyzine Hcl | 27 | $192 |
| Mirtazapine | 26 | $147 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Athens
- Rick BowersMoraine$182K
- Robert FindlingCleveland$125K
- Joseph RiemanFremont$56K
- Melissa DelbelloCincinnati$36K
- Andre ProchoroffCleveland$26K
- Peter GoldenAkron$21K
- Daniel WeisMiddletown$13K
- John VraciuCanton$11K
- Debra PankeMansfield$10K
- Barbara GraciousColumbus$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.